Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.57 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.55 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.51 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15057783 | 0.98 | GSK3B (0.62) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL255504 | 0.98 | GSK3B (0.67) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL10789142 | 0.83 | GSK3B (0.62) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL11510574 | 0.82 | GSK3B (0.71) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL240086 | 0.82 | GSK3B (0.71) | GSK3BTSHRCES1CA1CA2 | |
| Hydrochloric Acid SCHEMBL13738814 | 0.81 | GSK3B (0.42) | GSK3BTSHRCES1TDP1ALDH1A1 | |
| SCHEMBL10788268 | 0.80 | GSK3B (0.59) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL220960 | 0.80 | GSK3B (0.69) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL11713734 | 0.80 | GSK3B (0.69) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL16938818 | 0.80 | MAPT (0.63) | GSK3BTSHRCES1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106636239-B | Preparation method of chloramphenicol | 苏州引航生物科技有限公司 | 2019-12-31 | — | — | CN | claimed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | claimed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | claimed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | claimed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-115515934-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-4100393-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-10647673-B2 | Acetophenone compound, preparation method thereof, and application thereof in fatty liver prevention and treatment | Nanjing Bioenergy Medicine Science & Technology Co., Ltd. (CN) | 2020-05-12 | — | — | US | disclosed |
| CN-106636239-B | Preparation method of chloramphenicol | 苏州引航生物科技有限公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-106636239-B | Preparation method of chloramphenicol | 苏州引航生物科技有限公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190292153-A1 | Acetophenone Compound, Preparation Method Thereof, And Application Thereof In Fatty Liver Prevention And Treatment | Nanjing Bioenergy Medicine Science & Technology Co., Ltd. (CN) | 2019-09-26 | — | — | US | disclosed |
| WO-1998027108-A2 | NEW AMIDE COMPOUNDS AND THEIR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-25 | — | — | WO | disclosed |
| US-5041567-A | Human and veterianary medicine; veneral diseases respiratory diseases, bovine mastitis | BEECHAM GROUP PLC (GB) | 1991-08-20 | — | — | US | disclosed |
| EP-0131973-B1 | NEW AMIDINE DERIVATIVES OF 2-SUBSTITUTED 4-PHENILIMIDAZOLE | ISTITUTO DE ANGELI S.p.A. (IT) | 1989-08-02 | — | — | EP | disclosed |
| US-4812470-A | Antibacterial monic acid derivatives | BEECHAM GROUP P.L.C. (GB) | 1989-03-14 | — | — | US | disclosed |
| US-4649150-A | ANTISECRETORY AGENTS | ISTITUTO DE ANGELI, S.P.A. (IT) | 1987-03-10 | — | — | US | disclosed |
| EP-0131973-A1 | New amidine derivatives of 2-substituted 4-phenilimidazole | ISTITUTO DE ANGELI S.p.A. (IT) | 1985-01-23 | — | — | EP | disclosed |
| EP-0087953-A2 | Antibacterial 1-normon-2-yl-heterocyclic compounds | BEECHAM GROUP PLC (GB) | 1983-09-07 | — | — | EP | disclosed |
| US-4049650-A | 1-[[[5-(Substituted phenyl)-2-oxazolyl]methylene]amino]-2,4-imidazolidinediones | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | CA2 2464/4885GAA 2947/4885HSD11B1 1658/4885 |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | CA2 2982/4885GAA 331/4885HSD11B1 161/4885 |
| US-10647673-B2 | Acetophenone compound, preparation method thereof, and application thereof in fatty liver prevention and treatment | LIPC, CYP27A1, HSD17B10 | CA2 2946/4885GAA 418/4885HSD11B1 31/4885 |
| US-20190292153-A1 | Acetophenone Compound, Preparation Method Thereof, And Application Thereof In Fatty Liver Prevention And Treatment | LIPC, CYP27A1, HSD17B10 | CA2 2946/4885GAA 418/4885HSD11B1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.